JH
John P. Hamill
SrVP/CFO/Prin Fin & Acct Ofcr

John P. Hamill insider trades: Aprea Therapeutics (APRE) stock purchases

SrVP/CFO/Prin Fin & Acct Ofcr, Aprea Therapeutics Last trade Jan 30, 2026 21 Form 4 filings
$0
Sold, last 12 months
0 sales
$11K
Bought, last 12 months
2 buys
10
Open-market trades
since 2019
3
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where John reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 30, 2026APRE↑ Buy$5K
Dec 10, 2025APRE↑ Buy$6K
Oct 11, 2024APRE↑ Buy$123
Oct 10, 2024APRE↑ Buy$1K
Mar 13, 2024APRE↑ Buy$7K
Jul 26, 2022WINT↑ Buy$1K
Apr 16, 2021WINT↑ Buy$2K
Mar 25, 2021WINT↑ Buy$5K
Oct 7, 2020WINT↑ Buy$5K
May 31, 2019TRVN↑ Buy$9K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other APRE insiders

Open-market trades in the last 12 months

About John P. Hamill's insider trades

John P. Hamill is SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics (APRE). Since May 31, 2019, John has reported 10 open-market purchases worth $42K and no sales on SEC Form 4. In the last 12 months: 2 buys ($11K).

Their filings also include grants and awards (10 filings), other transactions (5 filings), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APRE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.